21.02.2020 • NewsDede WillamsMitsubishiTaiwan

Mitsubishi to Build Hydrogen Peroxide Plant in Taiwan

Mitsubishi to Build Hydrogen Peroxide Plant in Taiwan (c) mmmx/Shutterstock
Mitsubishi to Build Hydrogen Peroxide Plant in Taiwan (c) mmmx/Shutterstock

Mitsubishi Gas Chemical (MGC) is building a new 40,000 t/y plant for 100% industrial hydrogen peroxide (IHP) at a site owned by a subsidiary in Taiwan. The facility is expected to start up at the beginning of 2023.

The Japanese company said the investment is part of its plans to further develop its business with super-pure hydrogen peroxide (SPHP) used in semiconductor production processes, with the goal of participating in the long-term global growth of the semiconductor industry.

SPHP is used primarily as a cleaning, etching and abrading agent in semiconductor wafer and device manufacturing processes, which are expected to see long-term growth in line with  to future advancements in 5G, IoT, cloud computing, AI and other technologies.

The company sees demand as also as rising on the back of the trend to increasing miniaturization in semiconductor wiring processes, where greater volumes of SPHP featuring even higher quality will be needed.

MGC currently operates three SPHP production sites in Japan – at Yokkaichi, Yamakita and Saga – along with two in South Korea, three in the US and one each in Singapore and Taiwan.

 

Interview

Fostering Innovation and Collaboration
Specialty Chemicals Distributor IMCD’s Strategy

Fostering Innovation and Collaboration

Valerie Diele-Braun, CEO of IMCD, shares her vision for sustainability, global expansions, and strategic direction in an exclusive CHEManager International interview.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
27.03.2025 • News

J&J to Invest $55 Billion in US Operations

US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.

Photo
29.10.2024 • News

GSK to Invest $800 Million in US Manufacturing Facility

British pharma company GlaxoSmithKline (GSK) plans to invest up to $800 million to expand drug substance and drug product manufacturing capabilities at the company’s US site in Marietta, Pennsylvania. The investment, which GSK said is its largest ever in US manufacturing, is expected to create more than 200 new jobs.